Join The Discussion

 

Trademark closes on 63-acre Waterside site in Fort Worth

Construction begins Oct. 20 on the development, to be anchored by a Whole Foods Market.

read more >

UPDATE: $215M hotel, indoor ski project planned for Grand Prairie

Officials in Grand Prairie are expected later today to announce a $215 million project that will include a Hard Rock Hotel and an indoor ski facility.

read more >

Two Fort Worth council members propose temporary single-family moratorium around TCU

The moratorium would apply to new permits for single-family homes around TCU, and give the city time to figure out what to do with a controversial proposed overlay in several neighborhoods around the university.

read more >

Fresh Ebola fears hit airline stocks

DALLAS (AP) — News that a nurse diagnosed with Ebola flew on a plane full of passengers raised fear among airline investors that the scare over the virus could cause travelers to avoid flying.

read more >

Landscape architect behind several TCU landmarks acquired

The Dallas design firm behind several Texas Christian University projects, as well as Globe Life Park in Arlington and AT&T Stadium, has been acquired by Rvi Planning + Landscape Architecture.

read more >

Nicox, with Fort Worth operations, to acquire Aciex Therapeutics of Boston

Nicox S.A., an international ophthalmic company whose United States operations are based in Fort Worth, will acquire Aciex Therapeutics Inc., a private ophthalmic development pharmaceutical company in Boston, on a cash-free, debt-free basis through a reverse triangular merger.
Under terms of the proposed acquisition, Aciex shareholders will receive an upfront payment of $65 million in the form of 20,627,024 newly issued Nicox shares, plus contingent value rights giving right to shares for a potential additional value of up to $55 million.


The transaction will broaden and strengthen Nicox’s therapeutic development pipeline, which would include two phase 3 candidates, one being developed by Nicox’s partner Bausch + Lomb.
Aciex brings a near-term pipeline of ophthalmic therapeutic product candidates, including one for allergic conjunctivitis.
Aciex was founded in 2007 with technology licensed from Afferent Therapeutics LLC, a spin-out from Ora Inc.


The completion of the acquisition is subject to the approval of Nicox’s shareholders and other customary conditions.
Nicox was founded in 1996 and is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets, and an expanding international presence through partners. The company had a market cap of $271 million as of Feb. 28, 2014, and cash position of $86.1 million as of Sept. 30, 2013. Nicox employs about 134 people worldwide.
Nicox S.A. is listed on Euronext Paris.

Betty Dillard
bdillard@bizpress.net
 

< back

Email   email
hide
Ebola
How worried are you about Ebola spreading?